文献速递肝病

综述:微生物能否成为药物?益生菌与益生元治疗非酒精性脂肪性肝病的潜力

Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
PubMed 文献 · Aliment Pharmacol Ther · 2019-08-02

本文综述了肠道菌群在非酒精性脂肪性肝病(NAFLD)及非酒精性脂肪性肝炎(NASH)中的作用,并评估益生菌和益生元作为治疗策略的潜力。动物研究和初步人体研究显示,常见益生菌(乳杆菌、双歧杆菌、链球菌)及产短链脂肪酸(SCFA)丁酸的细菌有希望的结果,益生元对NAFLD-NASH的多种机制有正面效应。最有望的策略是益生菌和益生元,但治疗仍较新且在发展中,机制理解不足,治疗后肠道菌群变化很少被测量,缺乏大型对比终点临床试验。

要点

  • 益生菌和益生元是迄今开发的最有前景的调节NAFLD-NASH微生物组的策略。
  • 动物研究和初步人体研究显示乳杆菌、双歧杆菌、链球菌及产丁酸细菌有希望的结果。
  • 益生元对NAFLD-NASH的多种机制有正面效应。

核心结论

  • 益生菌和益生元是迄今开发的最有前景的调节NAFLD-NASH微生物组的策略,但治疗仍较新且在发展中。

研究设计与样本

  • 综述,通过PubMed检索NAFLD靶向肠道菌群的相关文献,检索词包括NAFLD、NASH、非酒精性脂肪性肝病、脂肪性肝炎,并结合微生物组、菌群、肠道细菌、益生菌和益生元。

主要发现

  • 动物研究和首批出现的人体研究显示,常见益生菌乳杆菌、双歧杆菌和链球菌以及产短链脂肪酸(SCFA)丁酸的细菌均有有希望的结果。
  • 益生元对NAFLD-NASH的多种机制有正面效应。

临床怎么用

  • 目前对益生菌和益生元治疗NAFLD-NASH的机制理解不足,且治疗后肠道菌群组成变化很少被测量。
  • 缺乏大型对比终点的临床试验,基于宏基因组肠道菌群分析的个体化治疗可能成为未来NAFLD-NASH诊断和治疗的一部分。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver condition. A major current research effort is ongoing to find potential strategies to treat NAFLD-non-alcoholic steatohepatitis (NASH), with special attention to the gut microbiota. Multiple animal studies and pilot clinical trials are assessing different gut microbiota modulating strategies such as faecal microbiota transplantation, antibiotics, probiotics, prebiotics and synbiotics. AIM: To review the role of microbiota in NAFLD-NASH and determine whether pro- and prebiotics have potential as treatment METHODS: Information was obtained from critically reviewing literature on PubMed on targeting the gut microbiota in NAFLD. Search terms included NAFLD, NASH, non-alcoholic fatty liver disease, steatohepatitis; combined with microbiome, microbiota, gut bacteria, probiotics and prebiotics. RESULTS: Animal studies and the first emerging studies in humans show promising results for both the common probiotics Lactobacillus, Bifidobacterium and Streptococci as for short chain fatty acid (SCFA) butyrate-producing bacteria. Also, prebiotics have positive effects on different mechanisms underlying NAFLD-NASH. CONCLUSIONS: The most promising strategies thus far developed to alter the microbiome in NAFLD-NASH are probiotics and prebiotics. However, pre- and probiotic treatment of NAFLD-NASH is relatively new and still under development. Actual understanding of the involved mechanisms is lacking and changes in the intestinal microbiota composition after treatment are rarely measured. Furthermore, large clinical trials with comparative endpoints are unavailable. Personalised treatment based on metagenomics gut microbiota analysis will probably be part of the future diagnosis and treatment of NAFLD-NASH.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Koopman N, Molinaro A, Nieuwdorp M, et al. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019. PMID: 31373710. doi:10.1111/apt.15416

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。